Peru Price Observatory and Public Procurement: Reporting Duties and Strategy

Regulatory information verified as of October 29, 2026

1. Key takeaways

Price reporting for medical devices in Peru is a data reporting obligation before the price observatory of the national product authority (Autoridad Nacional de Productos Farmacéuticos, Dispositivos Médicos y Productos Sanitarios, ANM), exercised through the General Directorate of Medicines, Supplies and Drugs (DIGEMID). It does not constitute price approval: reporting does not mean an approved price, nor does it confer pricing authority. Secondary sources record the device price reporting requirement as one of the contents of D.S. N° 020-2024-SA; this item is pending verification. Access to public procurement channels is subordinate to the tender requirements of each purchasing entity and is a practical estimate. For foreign manufacturers, the practical consequence is that price transparency in Peru is managed as a standing data obligation, while market access through public tenders is managed as a separate commercial capability, and neither can be outsourced to the other.

The GRZAN position is to manage price reporting as a disclosure obligation and to manage public channel transactions as an independent tendering capability; the two do not substitute for each other.

2. Legal basis

Regulatory information verified as of October 29, 2026. The number, publication date, and article content of D.S. N° 020-2024-SA have not been retrieved in original text from El Peruano and are marked site-wide as pending verification.

3. Expert insights

Insight one: reporting and approval are two acts of entirely different legal effect in administrative law. The mechanism of a reporting obligation is that the obligated party submits data in the prescribed format and frequency, the competent authority receives and aggregates the data without expressing approval or disapproval, and the obligated party may continue to trade at the reported prices. An approval, by contrast, creates a new administrative decision, and without approval the act cannot proceed. The functional positioning of the price observatory is data collection and monitoring in support of price transparency and policy analysis; therefore, treating the reporting receipt as evidence that a price has been approved is a misreading of the mechanism.

Insight two: the value of the observatory lies in building comparable data, not in setting prices. Once price data are centrally collected, the price distribution of the same product type and category becomes horizontally comparable. Mechanically, this changes market behavior: a reported price that is too high places the product at a disadvantage in subsequent procurement and policy discussions, while a reported price that is too low invites questions about the sustainability of costs and supply. GRZAN recommends keeping the reported figures consistent with genuine commercial pricing logic, avoiding unsustainable prices reported for short-term appearance.

Insight three: public procurement is a separate track; registration and reporting do not equal winning a tender. Transactions in the public channel are subordinate to the tender requirements and evaluation rules of each purchasing entity (a practical estimate). Mechanically, the sanitary registration settles whether a product may lawfully circulate, price reporting settles whether the price data have been collected, and procurement settles which one of several lawful products is selected. The three lines run in parallel, and none is automatically replaced by another.

Insight four: the overlap between the obligated party and the registration holder determines the execution arrangement. According to statistics derived from the official DIGEMID registry (Category C data, extracted on 2025-02-14), there are 1,688 registration holders corresponding to 28,819 valid registrations. The price reporting obligation falls on the domestic obligated reporting entities, and most foreign manufacturers still complete the submission through a registration holder (Titular del Registro Sanitario / Peru Registration Holder, PRH). GRZAN writes price reporting into the holding service agreement as a routine task of the PRH rather than an ad hoc matter.

Insight five: sanctions are measured in UIT, a different basis from official fees. The 2026 UIT is S/ 5,500 (D.S. N° 301-2025-EF, published on 2025-12-17, effective from 2026-01-01). Sanctions are measured in UIT, which belongs to a separate basis from the fixed sol amounts of the TUPA official fees, and the two should not be converted into each other. Secondary sources mention a sanction ceiling of 10 UIT; that amount is pending verification and must not be cited as a settled conclusion.

4. Practical recommendations

1. In the holding service agreement, define the submitting party, the frequency, and the data sources for price reporting, so the obligation does not fall into abeyance.
2. Establish an internal position that price reporting is not price approval, and align the understanding of the commercial and tendering teams.
3. Keep reported prices consistent with genuine commercial pricing, avoiding unsustainable prices reported for short-term appearance.
4. Before entering public channels, confirm the tender requirements and evaluation rules of the specific purchasing entity (practical estimate), without conflating them with registration status.
5. Keep tracking the primary verification outcome for D.S. N° 020-2024-SA, and do not rely on it as the basis of pricing compliance until the original text from El Peruano is obtained.
6. Conduct sanction risk assessment on the UIT basis, with the 2026 UIT at S/ 5,500; the ceiling of 10 UIT is a secondary source and pending verification.

5. Verification checklist

□ It has been confirmed that price reporting is a reporting obligation and not price approval.

□ Statements related to D.S. N° 020-2024-SA have been marked pending verification.

□ The submitting party and frequency of price reporting have been agreed in the holding service agreement.

□ Access to public procurement channels has been confirmed as subordinate to tender requirements (a practical estimate).

□ A sanction calculation basis has been established using the 2026 UIT of S/ 5,500.

□ It has been confirmed that the sanction ceiling of 10 UIT is a secondary source and is not cited as a settled conclusion.

□ The current verification of the 5-year validity period of the sanitary registration and the registry status has been completed.

□ Regulatory information verified as of October 29, 2026.

Regulatory information verified as of October 29, 2026.

GRZAN provides medical device registration support in Peru for manufacturers, importers, and authorized representatives. For inquiries, contact info@grzanglobal.com.

*GRZAN Regulatory Affairs Team*